We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Agilent and Sera Prognostics Enter Strategic Partnership
News

Agilent and Sera Prognostics Enter Strategic Partnership

Agilent and Sera Prognostics Enter Strategic Partnership
News

Agilent and Sera Prognostics Enter Strategic Partnership

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Agilent and Sera Prognostics Enter Strategic Partnership"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Agilent Technologies Inc. and Sera Prognostics Inc. have announced a strategic partnership to develop proteomic assays for the early prediction of pregnancy complications.

Sera Prognostics is currently developing a novel test for the early prediction of preterm birth risk using advanced proteomic science.

Agilent is a leading provider of a wide range of analytical instrumentation, including liquid chromatography, mass spectrometry and automation systems.

"By providing pivotal information to physicians, Sera's preterm birth predictor is designed to address an unmet medical need for a reliable, early risk assessment that has the potential to help significantly improve the health of mothers and newborns, while materially reducing the costs of care," said Gregory C. Critchfield, M.D., M.S., chairman and chief executive officer of Sera Prognostics.

Critchfield continued, "Our partnership with Agilent provides Sera with access to advanced and innovative technologies designed to deliver on the promise of personalized medicine."

"Agilent and Sera Prognostics share the vision of applying the power of advanced proteomic technologies to address meaningful medical challenges," said Yvonne Linney, VP and general manager of Agilent's Life Science Solutions Division.

Linney continued, "Agilent instrumentation is at the forefront of driving high-throughput workflows for sample preparation and mass-spec analysis that is critical in the field of proteomics."

As part of the partnership, Sera Prognostics purchased multiple Agilent 1290 Infinity ultra high-performance liquid chromatography systems, 6490 iFunnel triple quadrupole mass spectrometry systems and 1260 Infinity LC systems with ultraviolet detectors and is adapting Agilent's automated sample-preparation technologies for production.

The partners will develop high-throughput workflows for sample preparation and mass-spectrometry analysis.

To meet the demands of high-volume testing, Sera Prognostics expects to leverage Agilent's novel automated sample-prep technology and other automation, including the AssayMAP Bravo and RapidFire fast liquid chromatography together with ultra-sensitive ion funnel triple quadrupole mass spectrometry.

Advertisement